Fred Hutch Lung Cancer Program
Fred Hutchinson Cancer Center Lung SPORE
This program is developing new treatments for people with small cell and non‑small cell lung cancer, including options for KRAS‑mutant tumors and ways to improve response to immune therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11196682 on NIH RePORTER |
What this research studies
From a patient's perspective, this program brings together three projects focused on different treatment strategies for lung cancer. One project aims to change neutrophil behavior to help immune checkpoint drugs work better for non‑small cell lung cancer patients. Another project is developing engineered T cells to target KRAS‑mutant metastatic lung cancers, and the third looks at blocking LSD1 to make PD‑L1 inhibitors more effective in small cell lung cancer. These efforts are supported by cores that handle patient samples, statistics, and study coordination, plus development programs to move promising ideas toward clinical testing.
Who could benefit from this research
Good fit: Ideal candidates include people with small cell lung cancer, patients with metastatic KRAS‑mutant lung cancer, and non‑small cell lung cancer patients who are not responding adequately to immune checkpoint therapy.
Not a fit: People without lung cancer, or whose tumors lack the specific targets under study, are unlikely to receive direct benefit from these projects.
Why it matters
Potential benefit: If successful, the program could lead to more effective and personalized treatments for patients with SCLC, KRAS‑mutant lung cancer, or NSCLC who don't respond well to current immunotherapies.
How similar studies have performed: Immune checkpoint therapies have proven benefits for many lung cancer patients and engineered T‑cell therapies have shown promise in blood cancers, but applying T‑cells to KRAS‑mutant lung cancer and targeting neutrophils or LSD1 in lung tumors are newer strategies still under early testing.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Houghton, a Mcgarry — Fred Hutchinson Cancer Center
- Study coordinator: Houghton, a Mcgarry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.